GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (FRA:5DG) » Definitions » EV-to-FCF

Ocumension Therapeutics (FRA:5DG) EV-to-FCF : -6.00 (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ocumension Therapeutics's Enterprise Value is €417.10 Mil. Ocumension Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-69.46 Mil. Therefore, Ocumension Therapeutics's EV-to-FCF for today is -6.00.

The historical rank and industry rank for Ocumension Therapeutics's EV-to-FCF or its related term are showing as below:

FRA:5DG' s EV-to-FCF Range Over the Past 10 Years
Min: -11.56   Med: -5.58   Max: -2.35
Current: -4.87

During the past 6 years, the highest EV-to-FCF of Ocumension Therapeutics was -2.35. The lowest was -11.56. And the median was -5.58.

FRA:5DG's EV-to-FCF is ranked worse than
100% of 394 companies
in the Biotechnology industry
Industry Median: 4.23 vs FRA:5DG: -4.87

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), Ocumension Therapeutics's stock price is €0.84. Ocumension Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.076. Therefore, Ocumension Therapeutics's PE Ratio for today is At Loss.


Ocumension Therapeutics EV-to-FCF Historical Data

The historical data trend for Ocumension Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics EV-to-FCF Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - -21.97 -9.02 -9.38 -5.78

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -9.02 - -9.38 - -

Competitive Comparison of Ocumension Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Ocumension Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocumension Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's EV-to-FCF falls into.



Ocumension Therapeutics EV-to-FCF Calculation

Ocumension Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=417.097/-69.46
=-6.00

Ocumension Therapeutics's current Enterprise Value is €417.10 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ocumension Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-69.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocumension Therapeutics  (FRA:5DG) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Ocumension Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.84/-0.076
=At Loss

Ocumension Therapeutics's share price for today is €0.84.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ocumension Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.076.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Ocumension Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocumension Therapeutics (FRA:5DG) Business Description

Traded in Other Exchanges
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (FRA:5DG) Headlines

No Headlines